

ABSTRACT OF THE DISCLOSURE

Improved polynucleotide vaccine adjuvants and related polynucleotide vaccine
5 formulations are disclosed which are useful in prophylactic or therapeutic vaccine
and/or gene therapy-based applications. These adjuvants comprise a block copolymer
and a cationic surfactant component. The inclusion of a cationic surfactant results in
an increased percentage of polynucleotide that is physically associated with the
adjuvant *in vitro*, resulting in enhanced *in vivo* immune responses to polynucleotide
10 vaccines.

102390 4000000